Ambulatory blood pressure monitoring (ABPM) is a crucial tool for diagnosing primary and secondary hypertension, predicting cardiovascular disease and mortality, and identifying white-coat and masked subtypes. It provides a 24-hour account of a patient's state, with a diagnostic threshold of ≥130/80 mmHg over 24 hours. ABPM offers better prognosis of hypertension-mediated organ damage, is more sensitive to CV outcomes, and can provide stronger prognostic evidence.

Angiotensin receptor blockers (ARBs) and telmisartan have a renoprotective effect on renal endothelial function, preventing progression from microalbuminuria to macroalbuminuria, slowing the decline in glomerular filtration rate, and reducing proteinuria in overt nephropathy. ARB/ACEi combination therapy with SGLT2 inhibitors could achieve better control of blood pressure and estimated glomerular filtration rate. Combining SGLT2 with ACEi + ARB inhibitor reduced composite kidney outcome among T2DM patients with CKD. RSSDI guidelines provide comprehensive recommendations for managing hypertension in patients with diabetes. Non-pharmacological and pharmacological management of hypertension in diabetic patients are recommended, with ARBs, CCBs, ACE inhibitors, and beta-blockers often needed to achieve blood pressure goals

Angiotensin receptor blockers (ARBs) and telmisartan have a renoprotective effect on renal endothelial function, preventing progression from microalbuminuria to macroalbuminuria, slowing the decline in glomerular filtration rate, and reducing proteinuria in overt nephropathy. ARB/ACEi combination therapy with SGLT2 inhibitors could achieve better control of blood pressure and estimated glomerular filtration rate. Combining SGLT2 with ACEi + ARB inhibitor reduced composite kidney outcome among T2DM patients with CKD. RSSDI guidelines provide comprehensive recommendations for managing hypertension in patients with diabetes. Non-pharmacological and pharmacological management of hypertension in diabetic patients are recommended, with ARBs, CCBs, ACE inhibitors, and beta-blockers often needed to achieve blood pressure goals.

Ambulatory blood pressure monitoring (ABPM) is a crucial tool for diagnosing primary and secondary hypertension, predicting cardiovascular disease and mortality, and identifying white-coat and masked subtypes. It provides a 24-hour account of a patient's state, with a diagnostic threshold of ≥130/80 mmHg over 24 hours. ABPM offers better prognosis of hypertension-mediated organ damage, is more sensitive to CV outcomes, and can provide stronger prognostic evidence.

Ambulatory blood pressure monitoring (ABPM) is a crucial tool for diagnosing primary and secondary hypertension, predicting cardiovascular disease and mortality, and identifying white-coat and masked subtypes. It provides a 24-hour account of a patient's state, with a diagnostic threshold of ≥130/80 mmHg over 24 hours. ABPM offers better prognosis of hypertension-mediated organ damage, is more sensitive to CV outcomes, and can provide stronger prognostic evidence.

Ambulatory blood pressure monitoring (ABPM) is a crucial tool for diagnosing primary and secondary hypertension, predicting cardiovascular disease and mortality, and identifying white-coat and masked subtypes. It provides a 24-hour account of a patient's state, with a diagnostic threshold of ≥130/80 mmHg over 24 hours. ABPM offers better prognosis of hypertension-mediated organ damage, is more sensitive to CV outcomes, and can provide stronger prognostic evidence.

Cilnidipine is a novel, effective, and safe CCB that inhibits L-type and N-type calcium channels, regulating cardiac function. It is recommended for combination therapy in diabetic hypertensive patients to reduce cardiovascular and renal risks. ARBs, like telmisartan and losartan, are effective in reducing cardiovascular risk factors and renal complications. Cilnidipine's reno-protective and cardioprotective benefits make it the preferred choice for hypertensive patients with diabetes. Listen to the expert to know more on the Cilnidipine + ARB for Diabetic Hypertensives .

Angiotensin receptor blockers (ARBs) and telmisartan have a renoprotective effect on renal endothelial function, preventing progression from microalbuminuria to macroalbuminuria, slowing the decline in glomerular filtration rate, and reducing proteinuria in overt nephropathy. ARB/ACEi combination therapy with SGLT2 inhibitors could achieve better control of blood pressure and estimated glomerular filtration rate. Combining SGLT2 with ACEi + ARB inhibitor reduced composite kidney outcome among T2DM patients with CKD. RSSDI guidelines provide comprehensive recommendations for managing hypertension in patients with diabetes. Non-pharmacological and pharmacological management of hypertension in diabetic patients are recommended, with ARBs, CCBs, ACE inhibitors, and beta-blockers often needed to achieve blood pressure goals.